SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-23-071494
Filing Date
2023-12-19
Accepted
2023-12-19 16:15:16
Documents
20
Period of Report
2024-01-30

Document Format Files

Seq Description Document Type Size
1 DEF 14A abio-20231213.htm   iXBRL DEF 14A 716380
2 GRAPHIC img212962184_0.jpg GRAPHIC 9676
3 GRAPHIC img212962184_1.jpg GRAPHIC 9676
4 GRAPHIC img212962184_2.jpg GRAPHIC 20117
5 GRAPHIC img212962184_3.jpg GRAPHIC 18750
6 GRAPHIC img212962184_4.jpg GRAPHIC 9676
7 GRAPHIC img212962184_5.jpg GRAPHIC 978431
8 GRAPHIC img212962184_6.jpg GRAPHIC 268505
  Complete submission text file 0000950170-23-071494.txt   3919321

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT abio-20231213_pre.xml EX-101.PRE 10277
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT abio-20231213_def.xml EX-101.DEF 8536
11 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT abio-20231213.xsd EX-101.SCH 6918
12 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT abio-20231213_lab.xml EX-101.LAB 18417
15 EXTRACTED XBRL INSTANCE DOCUMENT abio-20231213_htm.xml XML 107891
Mailing Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021
Business Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021 7209402200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

IRS No.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-22873 | Film No.: 231497471
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)